Archer Aviation vs. Karman: Which Aerospace Stock Is a Better Buy in 2026?

The article favors Karman over Archer Aviation for 2026, citing Karman’s FY2025 revenue of $471.5 million, net income of $17.4 million, and 36.6% annual growth versus Archer’s $300,000 in revenue and $618.2 million net loss. Archer has a $1.5 billion conditional order book with United Airlines and $1.8 billion in cash at Q1, but it still faces FAA certification risk and ongoing losses. Karman’s stock is highlighted as a better buy after falling near its 52-week low of $43.49 despite record Q1 revenue of $151.2 million, up 51% year over year.

Analysis

The market is effectively pricing two different option profiles: ACHR is a long-dated venture-style call on certification and category creation, while KRMN is a cash-generative defense supplier with embedded growth and a much shorter path to monetization. The second-order issue is that capital markets tolerance matters more for ACHR than end-demand: if rates stay higher for longer or risk appetite fades, repeated equity raises can overwhelm any operating progress well before certification becomes investable at scale.

KRMN’s real advantage is not just profitability; it is program relevance in a defense capex cycle that still has multi-year visibility even if one customer slows. That makes it a better hedge against procurement volatility than the article implies, because missile defense, launch, and satellite spending are less correlated with commercial aerospace cycles and more tied to geopolitical budgets. The main caveat is customer concentration, but that cuts both ways: successful program expansion can scale quickly without needing consumer adoption or regulatory approval.

Consensus is likely underestimating how much time works against ACHR and how much optionality already exists in KRMN’s growth. ACHR can rerate sharply on a single certification or launch headline, but the distribution of outcomes is extremely fat-tailed negative until revenue becomes recurring. KRMN, by contrast, can compound through ordinary execution; the recent equity overhang creates an entry point, but only if investors believe dilution is a one-time event rather than a recurring funding tool.

Key Decisions for Investors

• Long KRMN on a 3-6 month horizon into pullbacks; risk/reward favors continued multiple support if revenue growth stays above 25% and FCF improves. Use the recent weakness as entry, with downside limited if defense sentiment remains constructive.
• Avoid or underweight ACHR in cash equity until certification and revenue conversion are visible; the stock remains a financing story more than an operating earnings story. If held, size as a small call option, not a core position.
• Pair trade: long KRMN / short ACHR to express 'execution over narrative' in aerospace over the next 6-12 months. This isolates balance-sheet and commercialization risk from sector beta.
• For tactical upside, use ACHR call spreads only into regulatory or launch catalysts, with defined premium at risk. This is a binary-event trade, not a buy-and-hold compounder.
• Watch for follow-on equity risk in ACHR and secondary issuance risk in KRMN; if either company taps capital markets again, reassess within days, not months, because dilution will likely dominate near-term returns.